One of the arguments used by the drug industry to justify high prices is the cost of developing a new therapy. That obviously doesn’t explain the ludicrous price increases we see from the industry, but lets just stick to the price of a new drug. A new analysis in the Journal of the American Medical Association Internal Medicine finds that, while not cheap, pivotal trials don’t appear to cost nearly as much as the drug industry would like us to believe. (JAMA Internal Medicine) These pivotal trials, often referred to as Phase III, are needed to be able to file a New Drug Application with the FDA and secure approval for marketing. These are typically the largest trials for the compounds and assess both safety and efficacy. The study included 59 therapeutic agents approved between 2015 and 2016, for which 138 pivotal clinical trials were conducted. Cost was estimated using a standard industry tool There was a substantial range in cost, over 100 times, with the median being $19 million. Half of the trials had costs between $12 and $19 million. Size of the trial was an obvious factor, as trials had from 15 to 8000 patients. Orphan drug pivotal trials, with the small patient sizes and no control group, cost as little as $5 million. A very large non-inferiority trial with clinical endpoints cost an estimated $345 million. Trials with no control group or no comparator drug group tended to cost almost a third less than trials with those features. Also, trials with longer trial and follow-up periods and with true clinical outcome endpoints had much higher costs. It is important to note that drugs with only incremental effects or improvements tend to require the largest, and therefore most expensive, trials, but do we really need many of these anyway? In general, this analysis makes me very leery of the very large development cost estimates we see for new drugs, and suggests that those with the most clinical improvement probably have the lowest development costs and therefore should have the lowest introductory prices, but don’t count on that.
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
Subscribe to Blog via Email
As is usually the case in health care, the big just keep getting bigger. UnitedHealth Group’s Optum division is buying NaviHealth, which helps manage post-acute care for Medicare Advantage members.
May 20, 2020
Stellar Health shines as it raises $10 million in new financing for its business of aiding providers and payers in doing value-based care.
May 14, 2020
Another typical post. For new readers, this blog usually is all health care business, policy, and research and one staple is me making fun of the ridiculous names people put...
May 7, 2020
MedPAC 2019 Report to Congress
June 18, 2019